Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. Several of the company's key product candidates, including UCART19, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is developing an anti-CD52 monoclonal antibody, ALLO-647, which is designed to be used prior to infusing its other product candidates as part of the lymphodepletion regimen.

Appian provides low-code automation platform that accelerates the creation of business applications, enabling its customers to automate their business. The company's platform automates the creation of forms, data flows, records, reports and other software elements that would otherwise need to be manually coded. The company'snSelf-Assembling Interface Layer technology ensures that applications developed on its platform can be deployed across a range of mobile and desktop devices, including desktop web browsers, tablets and mobile phones. The company's platform can be deployed in the cloud or on-premises, with organizations able to access the same functionality and data sources in various cases.

Eyenovia is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing the company's patented piezo-print delivery technology, branded the Optejet?. The company's MicroStat is a fixed combination formulation of phenylephrine-tropicamide for mydriasis (pupil dilation). MicroPine is a topical therapy for the treatment of progressive myopia. MicroProst is a latanoprost formulation for lowering intraocular pressure in patients with ocular hypertension, primary open angle glaucoma, and chronic angle closure glaucoma. MicroTears is the company's over-the-counter product candidate for hyperemia (red eye), pruritis (itch) and dry eye.

JELD-WEN Holding is a holding company. Through its subsidiaries, the company is a door and window manufacturer. The company designs, produces, and distributes a range of interior and exterior doors, wood, vinyl, and aluminum windows, and related products for use in the construction and repair and remodel of residential homes and, to a lesser extent, non-residential buildings. The company markets its products under the JELD-WEN brand, along with several brands such as Swedoor and DANA in Europe and Corinthian, Stegbar, and Trend in Australia. The company's customers include wholesale distributors and retailers as well as individual contractors and consumers. The company has three segments: North America, Europe, and Australasia.

Kingsway Financial Services is a holding company. Through its subsidiaries, Co. operates as a merchant bank engaged in the property and casualty insurance business. Co. operates three segments: Insurance Underwriting, which markets automobile insurance products that provide coverage in three main areas: liability, accident benefits and physical damage; Insurance Services, which includes IWS Acquisition Corporation, a licensed motor vehicle service agreement company, and Trinity Warranty Solutions LLC, a provider of warranty products and maintenance support; and Leased Real Estate, which includes Co.'s subsidiary, CMC Industries, Inc., that owns a parcel of real property located in Texas.

Safeguard Scientifics provides capital and relevant services for the growth of businesses in healthcare, financial services and digital media. The company's existing group of partner companies consist principally of technology-driven businesses in healthcare, financial services and digital media that are capitalizing on the enabling technologies, including enhanced security and predictive analytics. The company typically deploys up to $25 million in a company.

SeaChange International is engaged in the delivery of multiscreen, advertising and over the top video management solutions. The company's software products and services facilitate the aggregation, licensing, management and distribution of video and advertising content for service providers, telecommunications companies, satellite operators and broadcasters. The company sells its software products and services to service providers including: operators, telecommunications companies, satellite operators, and broadcasters. The company's business is focused on these product areas: video platform, content management, advertising and user experience. The company provides other services, maintenance and support for its products.

SecureWorks is a holding company. Through its subsidiaries, the company provides information security solutions focused on protecting its customers from cyber attacks. The company's integrated suite of solutions include: managed security, through which it provides its customers global visibility and insight into malicious activity enabling them to detect and remediate threats; and security and risk consulting, through which it advises its customers on a variety of security and risk-related matters. The company's proprietary Counter Threat Platform collects, aggregates, correlates and analyzes daily events from its customer base and uses algorithms to detect malicious activity and deliver security countermeasures.

TRACON Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. The company is developing its primary product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or in combination with inhibitors of the programmed cell death protein 1 pathway. The company's second clinical stage product oncology candidate is TRC102, a small molecule being developed for the treatment of lung cancer and mesothelioma.

oyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. The company is focused on neurological diseases with adeno-associated virus, gene therapy approach that either increases or decreases the production of a specific protein. The company's pipeline includes: Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis; Huntington's disease; Friedreich's ataxia; tau-related diseases including Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy; Alpha-synuclein related diseases for Parkinson's disease and other synucleinopathies; and severe, chronic pain.

Waitr Holdings operates an online food ordering and delivery platform that enables consumers to discover and order meals from local restaurants, powered by the company's team of delivery drivers. The company facilitates ordering of food and beverages by diners from restaurants for takeout and delivery through the Waitr Platform and also the Bite Squad Platform. The company markets its proprietary application and digital platforms to restaurants and diners mainly across small and medium sized markets. For diners, the company optimizes the journey from restaurant and food discovery through delivery, while providing restaurant selection.